SAVA vs. COLL, VRCA, NATR, SCPH, VSTM, CRNX, RARE, AXSM, CORT, and PBH
Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Collegium Pharmaceutical (COLL), Verrica Pharmaceuticals (VRCA), Nature's Sunshine Products (NATR), scPharmaceuticals (SCPH), Verastem (VSTM), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), and Prestige Consumer Healthcare (PBH). These companies are all part of the "pharmaceutical preparations" industry.
Collegium Pharmaceutical (NASDAQ:COLL) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.
38.1% of Cassava Sciences shares are held by institutional investors. 4.0% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 9.0% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Collegium Pharmaceutical has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500.
Collegium Pharmaceutical has a net margin of 16.46% compared to Collegium Pharmaceutical's net margin of 0.00%. Cassava Sciences' return on equity of 104.98% beat Collegium Pharmaceutical's return on equity.
Collegium Pharmaceutical received 282 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 66.43% of users gave Cassava Sciences an outperform vote while only 65.22% of users gave Collegium Pharmaceutical an outperform vote.
Collegium Pharmaceutical has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical currently has a consensus price target of $40.75, indicating a potential upside of 28.31%. Cassava Sciences has a consensus price target of $131.00, indicating a potential upside of 564.30%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Collegium Pharmaceutical.
In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 3 mentions for Collegium Pharmaceutical and 1 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 1.53 beat Collegium Pharmaceutical's score of 0.93 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.
Summary
Collegium Pharmaceutical beats Cassava Sciences on 12 of the 17 factors compared between the two stocks.
Get Cassava Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cassava Sciences Competitors List
Related Companies and Tools
